The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued positive opinions on several new products, including a gene therapy for Wiskott‑Aldrich syndrome developed with Telethon and regulatory endorsements for a Sanofi type‑1 diabetes drug and Eli Lilly’s oral SERD for breast cancer. The CHMP recommendations move these candidates toward EU marketing authorization. BioCentury and EMA notices list five products recommended by the committee; the Telethon gene therapy represents a notable academic‑to‑regulatory success after prior commercial setbacks for the asset. The CHMP’s endorsements reflect continued momentum for advanced biologics and targeted oncology agents in Europe. Developers will now prepare for European Commission decisions and country‑level rollout plans; positive CHMP opinions typically catalyze partnering and commercial planning.